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Background. Early detection is crucial for the prognosis of patients with autoimmune liver disease (AILD). Due to the relatively low
incidence, developing screening tools for AILD remain a challenge. Aims. To analyze clinical characteristics of AILD patients at
initial presentation and identify clinical markers, which could be useful for disease screening and early detection. Methods. We
performed observational retrospective study and analyzed 581 AILD patients who were hospitalized in the gastroenterology
department and 1000 healthy controls who were collected from health management center. Baseline characteristics at initial
presentation were used to build regression models. The model was validated on an independent cohort of 56 patients with AILD
and 100 patients with other liver disorders. Results. Asymptomatic AILD individuals identified by the health check-up are
increased yearly (from 31.6% to 68.0%, p < 0:001). The cirrhotic rates at an initial presentation are decreased in the past 18 years
(from 52.6% to 20.0%, p < 0:001). Eight indicators, which are common in the health check-up, are independent risk factors of
AILD. Among them, abdominal lymph node enlargement (LN) positive is the most significant different (OR 8.85, 95% CI 2.73-
28.69, p < 0:001). The combination of these indicators shows high predictive power (AUC = 0:98, sensitivity 89.0% and
specificity 96.4%) for disease screening. Except two liver or cholangetic injury makers, the combination of AGE, GENDER, GLB,
LN, concomitant extrahepatic autoimmune diseases, and familial history also shows a high predictive power for AILD in other
liver disorders (AUC = 0:91). Conclusion. Screening for AILD with described parameters can detect AILD in routine health
check-up early, effectively and economically. Eight variables in routine health check-up are associated with AILD and the
combination of them shows good ability of identifying high-risk individuals.
1. Introduction
Autoimmune liver disease (AILD) is the second commonest
cause of chronic liver disease in teenagers. There are several
forms including autoimmune hepatitis (AIH), primary bili-
ary cholangitis (PBC), primary sclerosing cholangitis (PSC),
PBC-AIH, and PSC-AIH overlap syndromes (OS) which
have common immunological characteristics and diagnosed
based on immunological markers and histology [1–4]. AILD
differs significantly in presentation and course depending
on the patient’s age at manifestation. Previous studies dem-
onstrated that more than one-third of AILD patients had
liver cirrhosis at the initial presentation, with the rate even
being higher in PBC-AIH OS [5–8]. Therefore, it is neces-
sary to develop a simple and reliable prognostic method
for early identification of patients with high risk for AILD
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and help guide clinicians to identify potential AILD patients
with maximized cost-effectiveness in primary and secondary
healthcare systems.
It has been reported that AILD patients with cirrhosis at
initial presentation have a substantially lower 10-year sur-
vival rate than patients without cirrhosis (61.9% vs. 94.0%)
[9]. The prognosis and survival time of AILD patients largely
depend on the development of liver cirrhosis and complica-
tions [10, 11]. Establishing practical methods for identifying
high-risk individuals of AILD prior to the development of
cirrhosis is crucial for improving the prognosis of patients
with AILD.
In our previous study, we observed that abnormalities of
several markers from routine health check-up, including
serum biochemistry tests, family history of autoimmune dis-
eases, and abdominal lymph node enlargement (LN) [12],
might be helpful for predicting individuals at high risk. Other
studies demonstrated that serum γ-globulins and abnormal
LN ultrasound results were associated with AILD [13, 14].
Moreover, it is about 20-50% AILD patients have a history
of other autoimmune diseases [15, 16], and 10-40% first-
degree relatives of patients have autoimmune disorders [17,
18]. Nevertheless, there is a lack of evaluation of common
clinical variables as the primary screening tool in clinical
practice. For the aim of detecting AILD risk from routine
health check-up, we analyze the clinical characteristics at ini-
tial presentation and select available indicators in health
check-up. With these common indicators utilizing in the
routine health check-up, we build up computational models
for the prediction of AILD risk at the early clinical stage.
2. Materials and Methods
2.1. Study Design and Participants. This study was a retro-
spective long-term cohort study of 602 patients admitted
to a single center from January 2001 to December 2017,
including 173 patients with AIH, 330 with PBC, 78 with
PBC-AIH OS, 19 with PSC, and 2 with Ig4 related liver dis-
ease. Informed written consent was obtained from all the
study participants. All the patients were admitted fulfilling
the diagnostic criteria of AILD, as proposed by diagnostic cri-
teria of AIH (v.1999), PBC (v.2009), and “Paris Criteria”
(v.1998) (Supplementary Materials—Participants (available
here)). Additionally, 1000 individuals from the health man-
agement center were included as a healthy control group.
We recruited a cohort of individuals with abnormal
liver function tests (LFTs) as validation cohort, which is
including 56 AILD patients and 100 non-AILD liver disease
cases with LFTs, including viral hepatitis, alcoholic liver dis-
ease, drug introduced liver injury, nonalcoholic fatty liver
disease, and obscure liver injury (Supplementary Table 1).
Both the AILD patients and non-AILD liver diseases were
continuously diagnosed in 2018. The inclusion criteria,
exclusion criteria, and the research design are shown in
Supplementary Figure 1.
2.2. Data Collection. Demographic, clinical, laboratory,
CT, and ultrasound imaging data of AILD patients were
derived from the patient clinical records of Tianjin Medical
University General Hospital (Supplementary Table 2). The
data derived from the medical records in patients with AILD
and healthy controls included age, gender, serum biochem-
ical parameters (TP, ALB, GLB, ALT, AST, ALP, GGT,
TBIL, and DBIL), LN, concomitant extrahepatic autoim-
mune diseases (CEAID), and familial history of autoimmune
disease (FA). FA and CEAID were recorded via telephone
follow-up interview, while cirrhosis was defined by CT
image or liver biopsy, and LN were diagnosed by abdominal
ultrasound [19]. FA was identified as at least one first-degree
relative with at least one autoimmune disease, included
AILD, autoimmune thyroid disease, Sjögren’s syndrome, and
rheumatoid arthritis. CEAID was defined as the patients
were diagnosed with both AILD and extrahepatic autoim-
mune disease, the details were shown in Supplementary
Table 3. To identify LN, the following criteria according to
Soresi et al. were applied: one or more masses with an ovoid
shape and less echogenic than the liver parenchyma,
separated from adjacent organs and vessels by a clear-cut
cleavage on repeated transverse, sagittal, and oblique scans
[19]. Investigation sites included the area of the trunk of the
portal vein, hepatic artery, celiac axis, superior mesenteric
vein, and pancreas head. The ultrasound was performed by
the same digestive specialist operator who was unaware of
the clinical, biochemical, and histologic data. The study
protocol adhered to the declaration of Helsinki and was
approved by the Institutional Ethics Committee of Tianjin
Medical University General Hospital.
2.3. Predictor Variables Selection. In order to select the AILD-
associated variables for further analysis, we performed corre-
lation analysis between the 14 indicators in the AILD cohort
and retained noncorrelated variables such as age, gender,
GLB, ALT, GGT, LN, CEAID, and FA for further analysis
(Supplementary Table 4). We tested these variables for
potential batch effects caused by the year of initial diagnosis.
Univariate logistic regression analysis was used to affirm
the association between each variable, and 8 variables were
found to be significant and selected for the construction
of AILD-risk models (Supplementary Materials—Choosing
Variables). A comparison of variables between AILD pa-
tients and healthy controls is shown in Table 1.
2.4. Construction and Model Validation. After incomplete
data filtering, we included 438 patients with AILD and 782
controls for model construction. All patients and controls
were randomly split into training group (75% of data) and
test group (remaining 25% of data). Models were trained
using logistic regression and classification and regression
trees (CART), with optimization performed by 3 repeats of
10-fold cross-validation on the training set. Model conver-
gence and training were assessed using learning curves
(Supplementary Figure 2). After establishing the first lo-
gistic regression model (Model 1) with 8 covariates, the two
markers of liver and cholangetic injury (ALT and GGT)
were subsequently excluded to better separate AILD pa-
tients and other abnormal LFTs cases. We trained logistic
regression model (Model 2) and CART model with the
remaining six variables (AGE, GEN, GLB, LN, CEAID, and
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FA). Details in the parameters of the CART model are
provided in Supplementary Materials—Classification and
Regression Tree [20].
The predictive power of models was calculated in the test
group and the external validation group (56 cases with AILD
and 100 controls with abnormal LFTs). The predictive power
of the model was evaluated by receiver operating characteris-
tic (ROC), area under the curve (AUC), accuracy, sensitivity,
and specificity.
2.5. Statistical Analysis.We reported frequency (percentages)
for categorical variables and median (range) for continuous
variables. We used Chi-squared test and Mann-Whitney U
test for comparisons of categorical and continuous variables,
respectively. More details in statistical methods are described
in Supplementary Materials—Descriptive analyses.
Correlation analyses and univariate logistic analyses were
performed with SPSS (version 23.0, IBM, USA). Establish-
ment and validation of the multivariate logistic regression
model and CART model were performed in the R software
(version 3.4.3.), using the caret package [21, 22]. Statistical
tests were considered significant at p < 0:05.
3. Results
3.1. Study Cohort and Baseline Characteristics. We studied a
total of 581 patients with AILD admitted to the hospital
between January 2001 and December 2017, with three main
subtypes: 173 AIH, 330 PBC, and 78 AIH-PBCOS. The num-
ber of newly diagnosed AILD patients increased yearly, from
3 cases in 2001 to 83 cases in 2017 (Supplementary Figure 3).
The demographic and biochemical characteristics of the
study population are outlined in Supplementary Table 2. The
median age of all patients was 59 years (maximum 88 years
and minimum 16 years), and the majority of the patients
were female (86.2%). Overall, 242 out of 581 patients were
asymptomatic (45%), and 191 patients had cirrhosis at first
diagnosis (33%) of which 68 (35.6%) patients underwent
liver biopsy. The characteristic of cirrhosis and noncirrhosis
group was shown in Supplementary Table 5.
3.2. Changing of Detection Ways and Cirrhosis Rate at
Diagnosis in AILD. AILD patients were classified into two
groups due to admission reasons: the health check-up group
referred to patients with abnormal LFTs or incidental find-
ings detected in health check-up; and the symptomatic group
included patients who had clinical symptoms, such as jaun-
dice, gastrointestinal bleeding, and abdominal pain.
We found that the proportion of patients in the health
check-up group increased from 31.6% before the year 2006
to 68.0% in the year 2017. This increase is statistically signif-
icant over the last 18 years (χ2 = 44:32, p < 0:001, Figure 1)
and demonstrates that regular health check-up has become
the key method to identify the individuals at high risk for
AILD.
We further analyzed the rate of cirrhosis at diagnosis in
AILD patients (Figure 2) and found that the proportion of
patients with cirrhosis at baseline gradually decreased from
52.6% before the year 2006 to 20.0% in the year 2017
(χ2 = 19:36, p < 0:001). The trend of decrease was found in
subgroups of AILD patients with AIH and PBC (χ2 = 16:00,
p < 0:001; χ2 = 6:95, p = 0:008). The proportion of cirrhosis
at baseline in patients with PBC-AIH OS showed a potential
trend of decrease over time (χ2 = 3:33, p > 0:05).
3.3. Risk Factors of AILD in the Health Check-Up. Compared
with healthy controls, 14 parameters measured during the
routine health check-up were significantly associated with
Table 1: Baseline characteristics of AILD cases and healthy controls.
Features All patients (n = 581) HC (n = 782) Statistic value∗ p value
Gender(female/male) 501/80 397/385 143.09 <0.001
Age, y (range) 59 (16-88) 51 (38-60) 9.47 <0.001
Biochemical parameters
TP (g/L) 76 (69-82) 74 (71-77) 3.01 0.003
ALB (g/L) 39 (34-43) 47 (45-48) 17.57 <0.001
GLB (g/L) 37 (32-42) 28 (25-30) 18.33 <0.001
ALT (IU/L) 73 (41-159) 17 (12-24) 20.69 <0.001
AST (IU/L) 76.9 (47-145) 18 (16-22) 23.02 <0.001
ALP (IU/L) 179 (115-328) 62 (52-74) 22.09 <0.001
GGT (IU/L) 191 (98-370) 21 (15-29) 21.92 <0.001
TBIL (μmol/L) 19.6 (12.8-42.5) 10.9 (8.3-14.0) 14.50 <0.001
DBIL (μmol/L) 7.6 (4.4-22.33) 4.0 (3.3-4.9) 13.46 <0.001
LN (%) 226 (38.9) 26 (3.3) 195.00 <0.001
CEAID (%) 257 (44.2) 39 (5.0) 167.19 <0.001
FA (%) 50 (8.6) 15 (1.9) 205.38 <0.001
∗Statistic value are calculated with the Chi-square test(χ2) in categorical variables and Mann-Whitney U test in numerical variables. Abbreviations: TP: total
protein; ALB: albumin; GLB: globulin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; GGT: gamma-glutamyl
transpeptidase; TBIL: total bilirubin; DBIL: direct bilirubin; LN: abdominal lymph node enlargement (B-mode ultrasound); CEAID: current extrahepatic
autoimmune diseases; FA: familial autoimmunity.
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AILD (p < 0:001, Table 1). After pairwise correlation analy-
sis, we excluded 6 parameters (TP, ALB, AST, ALP, TBIL,
and DBIL) that were strongly correlated with others. Conse-
quently, age, gender, GLB, ALT, GGT, LN, CEAID, and FA
were assumed as independent variables and used to construct
prediction models. The above eight variables were also found
to be associated with AILD in univariate analysis (Table 2).
The factor of positive abdominal lymph node enlargement
showed the most significant association within them (OR
19.46, 95% CI 10.91-34.69, p < 0:001).
3.4. Development and Validation of Models for Prediction of
AILD in Health Check-Up. We build a logistic regression
model for the identification of individuals at risk for AILD
with healthy check-up participants in eight predictors
(Model 1, Table 3) and evaluated this model using cross-
validation. The model showed high predictive power for
AILD in both the cross-validation set (Kappa = 0:87,
accuracy = 0:94, Supplementary Figure 2A) and the test set
composed of 25% of samples (AUC of 0.98; 95% CI 0.97-
0.99, sensitivity of 89.0%, specificity of 96.4%, and accuracy
of 93.7%, Figures 3(a) and 3(c)). The strongest predictor
was positive abdominal lymph node enlargement (OR 8.85,
95% CI 2.73-28.69).
We constructed a logistic regression model without the
variables of ALT and GGT, designed to separate AILD cases
from patients with other hepatic or cholangetic diseases
(Model 2, Table 3). This model showed high performance
in cross-validation set (Kappa = 0:75, accuracy = 0:89, Sup-
plementary Figure 2B) and the test set (AUC of 0.94; 95%
CI 0.92-0.96, sensitivity of 79.8%, specificity of 93.3%, and
accuracy of 88.5%, Figures 3(b) and 3(c)). Abdominal
lymph node enlargement positive result (OR 17.24, 95% CI
7.18-41.41) was also found to be the most influential
variable compared to others (Table 3).
Next, we tested these two models in a newly collected
cohort of 56 AILD patients and 100 individuals with other
liver diseases. Here, model without liver biomarkers (Model
2) showed higher performance (AUC 0.97, 95% CI 0.96 to












































































































































































Figure 1: Proportion of AILD patients diagnosed through regular health check-up. The proportion increased year by year (all: χ2 = 44:32,
p < 0:001; AIH: χ2 = 14:11, p < 0:001; PBC: χ2 = 18:97, p < 0:001; PBC-AIH OS: χ2 = 10:99, p < 0:001). p values were calculated by the
Trend Chi-square test. ∗∗∗ represents p value lower than 0.001, ns. represents no statistically significance.
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0.92 to 0.96). The exclusion of the two liver biomarkers,
which are not specific for AILD, increased both the sensi-
tivity and specificity of AILD prediction (87.5% and
95.0%; Figure 4).
3.5. Decision Tree Model Simplifies Prediction of AILD with
Health Check-Up Predictors. In order to find the best combi-
nation of predictors and their exact cutoff values, as well as
establish a visualization prediction model, we fitted a CART
model with six variables used for the training of Model 2.
The fitted decision tree is shown in Figure 5(a), and the
results of the evaluation on the external validation set are
shown in Figure 5(b). The model demonstrated good pre-
dictive power for the identification of AILD cases (AUC,
0.91, 95% CI 0.89-0.93, sensitivity of 85.7%, specificity of
92.0%). Consistent with the logistic regression model, ele-
vated GLB (≥34 g/L) was the most important discriminating
factor between high and low-risk AILD, while increased age
(>45 years), familial history of autoimmune disease and pos-
itive ultrasound finding of abdominal lymph node enlarge-









































































































































































Figure 2: The rate of liver cirrhosis in AILD patients at initial admission to the hospital. Except for PBC-AIH OS patients, the proportion of
liver cirrhosis was reduced year by year (all: χ2 = 19:36, p < 0:001; AIH: χ2 = 16:00, p < 0:001; PBC: χ2 = 6:95, p < 0:001; PBC-AIH OS:
χ2 = 3:33, p > 0:05). p values were calculated by the Trend Chi-square test. ∗∗∗ represents p value lower than 0.001, ns. represents no
statistically significance.
Table 2: Univariate regression analysis of factors measured by




SE (β) p value OR 95% CI
Gender (female) 2.07 0.19 <0.001 7.90 5.43–11.49
Age at
diagnosis (yrs)
0.07 0.01 <0.001 1.07 1.05–1.08
GLB (g/L) 0.30 0.02 <0.001 1.35 1.30–1.41
ALT (IU/L) 0.07 0.01 <0.001 1.07 1.06–1.08
GGT (IU/L) 0.03 0.002 <0.001 1.03 1.02–1.03
LN 2.97 0.30 <0.001 19.46 10.91–34.69
CEAID 2.05 0.20 <0.001 7.75 5.27–11.39
FA 2.80 0.28 <0.001 16.50 9.53–28.55
Log OR (β): logistic regression β coefficients (log odds ratio for one unit
increase in the explanatory variable); SE (β): standard error for the β
coefficient; OR: odds ratio for one unit increase in the explanatory variable
(exponential of β); 95% CI: 95% confidence interval for the odds ratio;
Abbreviations: AILD: autoimmune liver disease; GLB: globulin; ALT:
alanine aminotransferase; GGT: γ-glutamyltransferase; LN: abdominal
lymph node enlargement (B-mode ultrasound); CEAID: current extrahepatic
autoimmune diseases; FA: familial autoimmunity.
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4. Discussion
AILD is often asymptomatic at the early stage. Approxi-
mately 30% of patients have already developed cirrhosis
when the disease has been diagnosed, and such patients have
poor prognosis (e.g., lower survival rates). However, if
patients with AILD can be identified and diagnosed prior to
the onset of cirrhosis, treatments with immunosuppressive
agents could significantly improve the survival rates (from
62% to 94%) [10, 23]. While the management of AILD is cru-
cial, the early identification of the disease remains a chal-
lenge; currently no screening methods are available for
identifying individuals at risk of AILD [2]. To the best of
our knowledge, this is the first study that identified predictors
measured in routine health check-up for the early detection
of AILD.
In this study, we found that the proportion of cirrhosis in
AILD patients gradually decreased over the past 20-year
period (Figure 2). This is potentially because the increase in
regular health check-up attendance allowed the identification
of AILD patients with no clinical symptoms, but presented
abnormal LFTs in the health check-up and were referred to
a hepatologist for further diagnostic tests. This is in line with
the study that investigated diagnostic rates of autoimmune
hepatitis in Singapore, which concluded that the lack of
awareness of the primary health care professionals and the
public led to the delayed diagnosis and therapy of AIH
[24]. Our study further suggests that regular health check-
up may help improve early detection of individuals at high
risk for AILD.
We found that 14 parameters measured in routine
health check-up might contribute to the prediction models
for AILD (Table 1). Of these, we chose 8 uncorrelated fac-
tors (AGE, GENDER, GLB, ALT, GGT, LN, CEAID, and
FA) to build predictive models for identifying high-risk
AILD patients. Among the transaminase and bile enzymes,
AST and ALT, ALP and GGT are highly correlated. Previous
researches showed that ALT and GGT are more “early” and
“sensitive” indicators, which are more suitable for early
screening than AST and ALP [25, 26]. Therefore, we finally
chose ALT and GGT as the representative to enter the model
(Supplementary Table 4). Using these variables, we de-
veloped two prediction models for the identification of high
AILD risk: Model 1 is intended to be used in general health
check-up for the identification of AILD risk with clinical
variables, and we excluded LFTs in Model 2 to enable
estimation of AILD risk in individuals with abnormal LFTs,
to aim at identifying AILD from other liver diseases. While
detection of abnormal LFTs in health check-up has a
potential to identify AILD, it is not a specific marker because
LFTs are elevated in different liver diseases [27, 28]. Thus,
we used other parameters measured in the health check-up
to design model for the specific identification of AILD.
The Model 1 is built up for general healthy check-up to
identify high-risk AILD. Combined with the above clinical
variables, we found high predictive power in the internal
cross-validation (sensitivity is 89.0%, specificity is 96.4%,
Figure 3). Model 2 showed higher specificity and higher sen-
sitivity when tested using validation cohort of patients with
AILD and other liver diseases (Figure 4). This implies that
Model 2 without LFTs is better suited to the identification
of AILD from different liver disorders manifest with abnor-
mal LFTs. It is known that a family history of AILD and a his-
tory of other autoimmune diseases are risk factors for this
disease [29], that AILD was found mainly in middle-aged
women, and that serum γ-globulins and abnormal LN were
Table 3: Logistic regression models with predictive variables measured by routine health check-up.
Log OR (β) SE (β) p value OR (exp[β]) 95% CI OR
Model 1
Gender (male as reference) 1.74 0.46 <0.001 5.69 2.29–14.12
Age at diagnosis (years) 0.09 0.02 <0.001 1.10 1.07–1.13
GLB (g/L) 0.25 0.04 <0.001 1.28 1.19–1.38
ALT (IU/L) 0.04 0.01 <0.001 1.04 1.03–1.06
GGT (IU/L) 0.01 0.002 <0.001 1.01 1.006–1.014
LN 2.18 0.60 <0.001 8.85 2.73–28.69
CEAID 1.26 0.47 0.007 3.51 1.41–8.76
FA 1.92 0.53 <0.001 6.85 2.41–19.49
Model 2
Gender (male as reference) 1.53 0.33 <0.001 4.64 2.44–8.82
Age at diagnosis (years) 0.07 0.01 <0.001 1.07 1.05–1.10
GLB (g/L) 0.28 0.03 <0.001 1.32 1.26–1.39
LN 2.85 0.45 <0.001 17.24 7.18–41.41
CEAID 1.55 0.34 <0.001 4.72 2.41–9.23
FA 1.86 0.41 <0.001 6.41 2.84–14.44
Notes: Model 1 (M1) used the eight common variables after correlation analyses, and Model 2 (M2) used variables without liver- or cholangetic injury markers.
Abbreviations: AILD: autoimmune liver disease; GLB: globulin; ALT: alanine aminotransferase; GGT: γ-glutamyltransferase; LN: abdominal lymph node.
Enlargement (B-mode ultrasound); CEAID: current extrahepatic autoimmune diseases; FA: familial autoimmunity.
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associated with autoimmune hepatitis [2]. Among them,
enlarged abdominal lymph nodes are a typical ultrasound
feature, which is consistent with our results [30].
To demonstrate the possible implementation of our
model in the clinical practice, we constructed a decision-
tree based schematic for identification of AILD risk (CART








































AUC Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
Model 1 0.98 89.0 96.4 93.3 94.0 93.7
Model 2 0.94 79.8 93.3 87.0 89.2 88.5
(c)
Figure 3: Performance of the logistic regression models in clinical parameters measured from routine health check-up. (a) Receiver operating
characteristic curve (ROC) shows Model 1 had a good ability in predicting high-risk individuals with AILD in 8 variables, (b) Model 2 also
showed good prediction ability without liver- or cholangetic injury parameters, (c) performance of two models in the test group. AUC: area
under the receiver operating characteristic curve; PPV: positive predictive value; NPV: negative predictive value.
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model). This allowed us to quantify the cutoffs for selected
variables and to assess the risk for subgroups (Figure 5).
For example, the model predicts that individuals with GLB
≥ 34 g/L, older than 45 years, and with a family history of
AILD are at a very high risk of AILD (risk > 90%) and should
undergo further clinical tests for AILD diagnosis. While
AILD is a female-dominant disease, gender was not iden-
tified to be a critical variable in our decision tree model
(Figure 5(a)), possibly because it is mildly correlated with
GLB in our data (Spearman correlation 0.33). For clinical
practice, when an individual is judged to be “high risk” with
abnormal LFTs, it is necessary to conduct the immunology or
liver biopsy to further confirm the diagnosis of AILD, and it
is also necessary to have virology, blood lipid, B-ultrasound,
and other tests to estimate specific liver damages [31].
Since AILD is a rare disease (prevalence of 1-2 per
100,000 worldwide [32]), our models were, by necessity,
designed using relatively small samples and an unbalanced
ratio of cases and controls. Furthermore, while our model
did show high performance in the external validation cohort,
it might require further validation in cohorts from other
medical centers. Finally, the predictive model was designed
to supplement, rather than replace, the physician’s clinical
judgment and existing diagnostic criteria.
In summary, we demonstrate that models trained using



















M1 AUC = 0.94 (95%CI: 0.92−0.96)




AUC Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
Model 1 0.94 85.7 88.0 80.0 91.7 87.2
Model 2 0.97 87.5 95.0 90.7 93.1 92.3
(b)
Figure 4: Performance of external validation cohort in other liver injuries with abnormal LFTs. Validating the two logistic models in external
cohorts, (a) ROC shows a comparison of two models in the independent validation group, (b) performance of two models in the external
validation group, which shows Model 2 with six variables has better ability to identify AILD from other liver diseases. ROC: receiver
operating characteristic curve; AUC: area under the receiver operating characteristic curve; LFTs: liver function tests; PPV: positive
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N = 1220 (100%)
AILD 36%
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AUC = 0.91 (95%CI: 0.89−0.93)
(b)
Figure 5: Classification trees (CART) for predicting high-risk individuals of AILD. (a) CART tree for prediction visualization. The two sets of
numbers underneath each terminal node represent the proportions of patients or control subjects. The subgroups were marked with green
and blue according to prediction outcomes, e.g., subgroup 2 represents the group with the predictive pattern for the disease (probability of
AILD was 87%, dark green). The actual split values (thresholds) were indicated in the branches of the tree. HC: healthy controls; AILD:
autoimmune liver disease patients. (b) Receiver Operating Characteristic Curve. The CART model worked well in predicting high-risk
individuals with AILD in other liver injuries with an AUC of 0.91.
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during a routine health check-up enable reliable identifica-
tion of individuals at high risk for AILD. This approach could
be implemented in both primary and secondary health-care
settings to facilitate identification of noncirrhotic AILD
patients at the early stage, and thus help improve the progno-
sis of patients with AILD.
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